Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

MeiraGTx

Contributing Author

Recent Articles by MeiraGTx

Sep-23	MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors MGTX GlobeNewswire
Aug-13	MeiraGTx Reports Second Quarter 2026 Financial and Operational Results MGTX GlobeNewswire
Aug-06	MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MGTX GlobeNewswire
Aug-06	MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MGTX GlobeNewswire
Jul-07	MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec) MGTX +5.54% GlobeNewswire
May-14	MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MGTX MGTX -5.53% GlobeNewswire
May-14	MeiraGTx Reports First Quarter 2026 Financial and Operational Results MGTX GlobeNewswire
Apr-16	MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares MGTX -15.73% GlobeNewswire
Apr-16	MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) MGTX -15.73% GlobeNewswire
Apr-16	MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia MGTX -15.73% GlobeNewswire
Apr-14	MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 MGTX +17.24% GlobeNewswire
Mar-26	MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results MGTX GlobeNewswire
Nov-13	MeiraGTx Reports Third Quarter 2025 Financial and Operational Results MGTX GlobeNewswire
Nov-10	MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology MGTX GlobeNewswire
Oct-07	MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress MGTX GlobeNewswire
Aug-14	MeiraGTx Reports Second Quarter 2025 Financial and Operational Results MGTX GlobeNewswire
May-13	MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting MGTX -8.36% MGTX -10.00% GlobeNewswire
May-13	MeiraGTx Reports First Quarter 2025 Financial and Operational Results MGTX -8.36% GlobeNewswire
May-09	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease MGTX GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)